

Patient Addressograph

Note: These orders apply to newborn to 16 years; intended for care provided within a Pediatric/Neonatal Intensive Care Unit. Dosages and infusion rates listed below reflect those used at BC Children's Pediatric ICU and apply to children less than or equal to 60 kg, beyond which adult dosing should apply.

| Contact BC Children's Hospital PICU 604-875-2133 for any quest | tions. |
|--|--|
| | |
| Date: Time: | |
| Admission Instruction ☑ Comfort Care Note x2 in chart (by 2 attending physicians) ☑ Contact initiated with BC Transplant ☑ Consent for Organ Donation obtained by BCT coordinator ☑ Code Status: Full therapy except cardiopulmonary resuscitation | |
| SECTION I. GUIDELINE FOR POTENTIAL DCD PATIEN | IT UNTIL WITHDRAWAL OF LIFE SUPPOR |
| MONITORING ✓ Complete patient actual height and weight. Record on BCT Physi (Available on www.transplant.bc.ca) ✓ Urine output q1h ✓ HR, BP, temperature, pulse oximetry q1h ✓ Arterial pressure monitor continuous PATIENT CARE ✓ Central venous catheter ✓ Urine catheter | General Targets: Age-related norms for pulse and blood pressure (BP) CVP 6-10 mmHg (fluid resuscitation to maintain normovolemia) Urine Output 0.5 to 3 mL/kg/h Hemoglobin (Hgb): above 70 g/L |
| ✓ Maintain head of bed greater than 30 degrees ✓ Targeted temperature management goal 35.5 – 37.5°C | |
| ✓ NG/OG to low intermittent suction if feeds contraindicated or not to | plerated |
| LABORATORY INVESTIGATIONS | |
| $\ \ \ \ \ \ \ \ \ \ \ \ \ $ | d Blood Box") |
| Initial Bloodwork, then q8h ☑ ABG ☑ Na, K, CI,Bicarb, SCr, Urea, Ca, Mg, PO4, Lactate, eGFI ☑ INR/PTT, AST, ALT, TBil, DBil, ALP, GGT, LDH, Total Pi ☑ Albumin, Amylase/Lipase, CK, Troponin (I or T) | |

| Date (dd/mm/yyyy) | Time | Prescriber's Signature | Printed Name or College ID# |
|-------------------|------|------------------------|-----------------------------|
| 1 1 | | | |



Patient Addressograph

| ☑ Goal hemoglobin greater than 70 g.☑ Monitor platelet level. Notify physici | /L. Notify physician and BCT if <70 g/L ian and BCT if < 10 (consider transfusion) | |
|---|---|----------------------------------|
| ☑ Urinalysis including specific gravity,☑ Urine microalbumin/creatinine (ACF | routine and micro baseline and Q24h R) ratio baseline and PRN as requested | |
| <u>DIAGNOSTICS</u> | | |
| ☑ CXR daily | | |
| ☐ CT of chest and abdomen (if reque | sted by BC Transplant: High resolution – No | n contrast) |
| ☐ Bronchoscopy (if requested by BC | | , |
| complete Bronchoscopy form | available on www.transplant.bc.ca | |
| NUTRITION | | |
| | nitiate unless contraindicated. (Hold feed 8 I | nours prior to recovery surgery) |
| ☑ If patient on parenteral nutrition, co | nsult dietician for direction | |
| INTRAVENOUS | | |
| ☑ Total fluid intake at_mL/h | | |
| ☑ Fluid type: | | |
| (As per standard fluid managemen | t protocols – 80% maintenance) | |
| Lung recruitments not indicate Goal to optimize PEEP for inc Pulmonary toileting and chest | • | |
| ☑ Continue mechanical ventilation as *OR* | per previous orders | |
| Mechanical ventilation as follows: Mode Tidal volume 6-8 ml /kg IBW 6-8. | OR pressure limit at(cm H2O) as a | nnlicable |
| | to meet patient requirements (may require h | |
| , | ter than or equal to 95% Maintain PaO2 grea | ater than 70 mmHg with minimal |
| effective FiO2. ☑ Maintain pH 7.35 to 7.45 | | |
| • | ent PEEP for 10 minutes initial and q6h | |
| | | |
| Date (dd/mm/yyyy) Time | Prescriber's Signature | Printed Name or College ID # |



Patient Addressograph

MEDICATIONS

Hemodynamic Monitoring and Therapy:

| Heart Rate | | | | |
|---|---------|--------|--|--|
| Normal Heart Rate by Age (beats/minute) Reference: PALS Guidelines, 2015 | | | | |
| Age Awake Sleeping Rate Rate | | | | |
| Neonate (<28 d) | 100-205 | 90-160 | | |
| Infant (1 mo-1 y) | 100-190 | 90-160 | | |
| Toddler (1-2 y) | 98-140 | 80-120 | | |
| Preschool (3-5 y) | 80-120 | 65-100 | | |
| School-age (6-11 y) | 75-118 | 58-90 | | |
| Adolescent (12-15 y) | 60-100 | 50-90 | | |

| Respiratory Rate | | | |
|--|-------|--|--|
| Normal Respiratory Rate by Age (breaths/minute) Reference: PALS Guidelines, 2015 | | | |
| Age Normal Respiratory Rate | | | |
| Infants (<1 y) | 30-53 | | |
| Toddler (1-2 y) | 22-37 | | |
| Preschool (3-5 y) | 20-28 | | |
| School-age (6-11 y) | 18-25 | | |
| Adolescent (12-15 y) | 12-20 | | |
| | | | |

| ы | 00 | a | ۲ľ | es | su | re |
|---|----|---|----|----|----|----|
| | | | | | | |

| Normal Blood Pressure by Age (mm Hg) Reference: PALS Guidelines, 2015 | | | | |
|--|-------------------|--------------------|--------------------------|--|
| Age | Systolic Pressure | Diastolic Pressure | Systolic Hypotension | |
| Birth (12 h, <1000 g) | 39-59 | 16-36 | <40-50 | |
| Birth (12 h, 3 kg) | 60-76 | 31-45 | <50 | |
| Neonate (96 h) | 67-84 | 35-53 | <60 | |
| Infant (1-12 mo) | 72-104 | 37-56 | <70 | |
| Toddler (1-2 y) | 86-106 | 42-63 | <70 + (age in years x 2) | |
| Preschooler (3-5 y) | 89-112 | 46-72 | <70 + (age in years x 2) | |
| School-age (6-9 y) | 97-115 | 57-76 | <70 + (age in years x 2) | |
| Preadolescent (10-11 y) | 102-120 | 61-80 | <90 | |
| Adolescent (12-15 y) | 110-131 | 64-83 | <90 | |

Reference: from https://www.pedscases.com/pediatric-vital-signs-reference-chart

Notify physician if outside of general target parameters

| Management of Hy | unotension: Targe | at RP | 1 |
|------------------|-------------------|-------|---|
| Management of m | vootension. Tarde | FIDE. | / |

| Pediatric patients will often be on epinephrine due to hemodynamic instability. The cardiac transplant progi | rams |
|--|------|
| preference is for this to be transitioned to alternative agents for maintaining normal blood pressures. | |

| □ vasopressin | milliunit/kg/min (0.3 to 2 milliunit/kg/min) IV infusion Max. dose: 40 milliunit/min |
|-------------------------|--|
| □ NORepinephrine | mcg/kg/min IV infusion (0.01 to 0.2 mcg/kg/min; |
| caution with doses grea | iter than 0.2 mcg/kg/min; max 2 mcg/kg/min) |

Management of Hypertension: Target BP: /

Age-related Treatment Thresholds for Arterial Hypertension:

Newborns to 3 months
 3 months to 1 year
 1 year to 12 years
 12 years to 18 years
 greater than 90/60 greater than 110/70 greater than 130/80 greater than 140/90

a. If necessary start:

| ☐ nitroprusside | mcg/kg/min (0.5 to 5 mcg/kg/min) OR |
|-----------------|--|
| □ esmolol | mcg/dose (500 mcg/kg/dose) IV bolus over 1-2 min |
| Followed by | _mcg/kg/min (50 to 300 mcg/kg/min) IV infusion |

| Date (dd/mm/yyyy) | Time | Prescriber's Signature | Printed Name or College ID# |
|-------------------|------|------------------------|-----------------------------|
| 1 1 | | | |



Patient Addressograph

<u>Diabetes Insipidus (DI)</u> (MD to confirm diagnosis, less common in DCD patients)

Defined as urine output greater than 3 mL/kg/h associated with:

- increasing serum sodium greater than 145 mmol/L and/or
- increasing serum osmolarity greater than 300 mosM, and/or
- decreasing urine osmolarity less than or equal to 200 mosM

| If Diabetes Insipidus present, titrate therapy to urine output less than 3 mL/kg/h |
|--|
| milliunit/kg/min (0.02-0.0.05 milliunit/kg/min) IV infusion |
| Max. dose: 0.2 milliunit/kg/min |
| |
| INFECTION SURVEILLANCE AND TREATMENT |
| Examine patient each shift for new skin lesions suggestive of viral, fungal or bacterial infection |
| On daily rounds review for potential new infection. |
| Treat any new suspected or confirmed viral, fungal or bacterial infection and notify BC Transplant |
| Influenza test (Flu A/B/RSV) all donors (during flu season only, typically Dec 1 to Mar 31. COVID-19 test (requires dual source – NP swab and ET specimen test as indicated by BC Transplant). Must be completed within 5 days of recovery surgery. |
| Oral and genital swabs of any potential viral lesions, consult BC Transplant for recommended testing |
| Cultures - all cultures to be done at baseline and then q24h |
| Sputum gram stain and culture |
| Blood culture (Refer to current BCCH Pediatric Blood Culture Guide for appropriate collection quantities) |
| Urine culture |
| Culture all drain sites MRSA and VRE screens (also screen all drain sites for MRSA) as per hospital policy |
| Antifungals and Antibiotics |
| Consult pharmacy for renal dosing of all antibiotics in presence of impaired renal function If lungs <u>not</u> considered, treat any known or suspected infections as per ICU direction If lungs are being considered treat with the following: |
| ☐fluconazole 6 mg/kg/dose (max 400 mg) IV q24h |
| □vancomycin (15 mg/kg)mg IV q6h |
| (*round to nearest 250 mg) (consult pharmacy for renal dosing in presence of AKI) |
| And one of the following: |
| □ piperacillin-tazobactam 75 mg/kg/dose of piperacillin component (max 4 g/dose) IV q6h *OR* |

meropenem 20 mg/kg/dose (max 2 g/dose) IV q8h (If documented or suspected penicillin anaphylaxis or history of

Date:15-Sep-2023

Prescriber's Signature

Date (dd/mm/yyyy)

Extended Spectrum Beta-Lactamase (ESBL) organisms)

Time

Printed Name or College ID #



Patient Addressograph

SECTION II. WITHDRAWAL OF LIFE SUPPORT

| _ | Concult | ICII for | Comfort | Caro | ordore |
|---|---------|----------|---------|------|--------|
| • | Consun | IGU IOF | Comion | Care | orders |

| | units IV n 60 mmHg at impending death (RN to consult with ICU attending for timing of administration) |
|--------------------|--|
| Symptom Management | |
| Pain/discomfort | |
| ☐ Morphine | _(0-20 mcg/kg/hour) IV infusion |
| ☐ Morphine | _(0.05-0.1 mg/kg) IV q30min prn |
| ☐ Midazolam | _(0-100 mcg/kg/hour) IV infusion |
| ☐ Midazolam | (0.05-0.1 mg/kg) IV q30min prn |
| ☐ Other | |
| ☐ Other | |
| Other | |

| Date (dd/mm/yyyy) | Time | Prescriber's Signature | Printed Name or College ID # |
|-------------------|------|------------------------|------------------------------|
| 1 1 | | | |